Newsletters

[Biomaterials Advances] To improve wound healing potential, scientists sought to enhance the collagen-glycosaminoglycan scaffold's pro-angiogenic and pro-neurogenic capacity through addition of fibronectin, collagen IV, or laminin 1 to the scaffold, key extracellular matrix components known to support angiogenic and neurogenic processes.

[Biomaterials] Using biofunctional bone matrix models, investigators found that mineralization prevents mesenchymal stem cell-mediated collagen remodeling by limiting actomyosin contractility while promoting osteogenic differentiation.

[Cardiovascular Research] The authors revealed a novel epitranscriptomic pathway wherein YTHDF1 recognizes m⁶A-modified Runx1 mRNA, enhancing its translation and thereby stimulating RUNX1-mediated Ctgf transcription.

[Biofabrication] Inspired by the interactions between the extracellular matrix and growth factors in vivo, this study develops a polyanionic hydrogel system for the controlled delivery of basic fibroblast growth factor to regulate healing processes.

[Cell Death & Disease] Investigators revealed a novel inhibitory role of 14-3-3γ in matrix mineralization of human adipose-derived mesenchymal stem/stromal cells, suggesting that targeting this paralog may offer new avenues for therapies in bone remodeling disorders.

[Cellular & Molecular Biology Letters] Targeting fibroblast activation protein as a strategy for treating renal fibrosis was tested using two preclinical animal models: the mouse models of unilateral ureteral obstruction and unilateral renal ischemia–reperfusion.

[Biomacromolecules] The authors summarize progress in the design and application of ECM-mimetic peptides, focusing on their roles in tissue engineering, regenerative medicine, and drug delivery.

[ACS Biomaterials Science & Engineering] Scientists provide a detailed overview of in vivo bone regeneration strategies for critically sized defects, specifically within compromised healing environments, summarizing how animal models are developed and how biomaterial, cellular, and drug delivery platforms are tailored to these disease states.

[Agomab Therapeutics NV (Globe Newswire)] Agomab Therapeutics NV announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,577,230 for AGMB-447, to Agomab. AGMB-447 is the investigational inhaled lung-restricted small molecule inhibitor of ALK5, currently in a Phase Ib study for the treatment of idiopathic pulmonary fibrosis.

[Nature Reviews Immunology] Recent genomic and mechanistic studies reveal that peripheral T cell lymphomas frequently ‘hijack’ signaling pathways that normally govern T cell activation at the immunological synapse.

[Nature Communications] Researchers uncovered a role for IgA autoantibodies in Hidradenitis suppurativa, implicating them as central drivers of chronic inflammation, fibrosis, and immune crosstalk across neutrophils, macrophages, fibroblasts, and T cells.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists presented an in-depth characterization of peripheral and intrathecal immune cell populations in individuals with anti-GAD65 autoimmune neurological syndromes compared with noninflammatory and healthy controls, using multidimensional flow cytometry, histology, and single-cell RNA sequencing combined with immune repertoire profiling.